Seminars in Nephrology
Volume 26, Issue 3 , Pages 234-243 , May 2006

Vaptans and the Treatment of Water-Retaining Disorders

  • Friedericke Quittnat
    • ,
  • Peter Gross

      Affiliations

    • P.G. has been an investigator in clinical study protocols of vasopressin antagonists from Wyeth Ayerst (lixivaptan or VPA 985), Münster, Germany; from Astellas (conivaptan or YM 087), Heidelberg, Germany; from Sanofi Recherche (SR 121 463 B), Berlin, Germany; and from Otsuka Pharmaceutical Co. Ltd. (tolvaptan, OPC 41061), Frankfurt, Germany.
    • Corresponding Author InformationAddress reprint requests to Peter Gross, MD, Nephrologie, Medizinische Klinik III, Universitätsklinikum C.G. Carus, Fetscherstrasse 74, D-01307 Dresden, Germany.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0270-9295(06)00014-3

doi: 10.1016/j.semnephrol.2006.02.003

Seminars in Nephrology
Volume 26, Issue 3 , Pages 234-243 , May 2006

Article Tools

* Image Usage & Resolution